Adage Capital Management
Adage Capital is a Boston-based hedge fund founded by Phillip Gross which held nearly $24 billion in securities at the end of the quarter ended September 30, 2010.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
View Older Stories View More Recent Stories
-
Karyopharm Therapeutics (KPTI) Announces $165 Million Private Placement
-
Karyopharm Announces $165 Million Private Placement
-
Form SC 13G Stronghold Digital Minin Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Farallon, Franklin Templeton among potential winners in Twitter
-
Form 13F-HR ADAGE CAPITAL PARTNERS For: Sep 30
-
Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
-
BioAtla (BCAB) Sells 9.745M Shares at $6.67
-
BioAtla Announces $65 Million Underwritten Offering of its Common Stock
-
BioAtla Announces $65 Million Underwritten Offering of its Common Stock
-
Rain Therapeutics (RAIN) Prices 6.86M Share Offering at $5.83/sh
-
Rain Therapeutics Announces $50 Million Registered Offering of Common Stock
-
Abeona Therapeutics (ABEO) Prices 7.6M Share Private Placement at $4.6/sh
-
Abeona Therapeutics Announces $35 Million Private Placement Financing
-
Abeona Therapeutics Announces $35 Million Private Placement Financing
-
Compass Therapeutics (CMPX) Prices 25M Share Private Placement at $3.21/sh
-
Compass Therapeutics Announces $80 Million Private Placement
-
Form SC 13G Travere Therapeutics, Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Investors who stuck it out for Musk's Twitter deal set to reap rewards
-
Form SC 13G IDEAYA Biosciences, Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13D/A Gemini Therapeutics, Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13D Gemini Therapeutics, Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Immunic Inc. (IMUX) Announces Oversubscribed $50M Private Placement at $4.35/sh
-
Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing
-
Form SC 13G ADAMS NATURAL RESOURCES Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Ventyx Biosciences (VTYX) Announces $176.6 Million Private Placement of Common Stock
-
Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock
-
Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
-
TYME Technologies, Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote “FOR” Proposed Merger of Syros and Tyme
-
Form SC 13G Provention Bio, Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G 89bio, Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
-
Form SC 13D East Resources Acquisiti Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G Annexon, Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G NEWPARK RESOURCES INC Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025
-
Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025
-
Form SC 13G SK Growth Opportunities Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Annexon (ANNX) Announces $130 Million Private Placement Financing
-
Annexon Announces $130 Million Private Placement Financing
-
Annexon Announces $130 Million Private Placement Financing
-
Syros Pharmaceuticals (SYRS) to Raise Approximately $190 Million Through Merger with TYME Technologies (TYME) and Concurrent Private Placement
-
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
-
Form SC 13G Rezolute, Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq®)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb's iPREDICT Phase IIb Study
-
Imaging Endpoints (IE) and ImaginAb Inc Expand Partnership - IE to Supply Clinical Doses of CD8 Imaging Agent to BioPharma Companies
-
Form SC 13G ArcLight Clean Transitio Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
ImaginAb and [Yantai] DongCheng Pharmaceutical Group Sign Exclusive License Agreement to Commercialize CD8 ImmunoPET Agent in China to Serve Pharma and Healthcare Community
-
Form SC 13G Investcorp India Acquisi Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form 13F-HR ADAGE CAPITAL PARTNERS For: Mar 31
-
Form SC 13G Chenghe Acquisition Co. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.

